GlassScriptPhysician profile
Rebekah E Doty
NPI 1790332450
$2,665.09
in general payments reported to CMS, 2019-2025
22 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $470 · 2023: $756 · 2024: $613 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.34 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $276.78 | 2021-2024 | Farxiga, Breztri |
| Inspire Medical Systems, INC. | $266.05 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $262.02 | 2021-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $204.52 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $124.41 | 2022-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $116.26 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.97 | 2021-2024 | Tradjenta, Jardiance |
| Exact Sciences Corporation | $87.44 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $86.57 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.17 | 2021-2024 | Caplyta |
| Mylan Specialty L.P. | $64.87 | 2021-2024 | Yupelri |
| Philips North America LLC | $57.24 | 2023 | |
| Lundbeck LLC | $48.07 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $47.50 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $42.02 | 2023-2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $26.95 | 2021-2023 | Veozah |
| Merck Sharp & Dohme LLC | $23.90 | 2024 | Vaxneuvance, Gardasil 9, Proquad |
| Sanofi Pasteur INC. | $23.78 | 2023 | |
| Ironshore Pharmaceuticals INC. | $22.38 | 2023 | Jornay Pm |
| Agile Therapeutics, INC. | $16.99 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.86 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.